Dr Robert Hewitt is a Biobanking Specialist.
Previously, Robert worked in cancer research, both as a lecturer in pathology, at the University of Nottingham; and as a visiting fellow, at the National Institutes of Health. Since 1998, he has established/managed biobanks in London, Saudi Arabia, Singapore and Luxembourg. He was President of ISBER in 2007 and moved on to co-found ESBB in 2010, serving as the sole employee until 2017. After one year of industry experience, working for Trans-Hit Biomarkers, Robert now works independently as a consultant, promoting cooperation between academic biobanks and industry. He is active on LinkedIn and runs the ‘Drug Targets & Biomarkers’ group.
